Amarin announced the availability of Vascepa (icosapent ethyl) 0.5g capsules, a smaller size launched in addition to the currently available 1g capsules. 

Vascepa was initially approved by the Food and Drug Administration (FDA) in July 2012 as adjunct to diet to reduce triglyceride (TG) levels in adults with severe (≥500mg/dL) hypertriglyceridemia. The new capsule size is the first half-gram prescription omega-3 option for patients who prefer a smaller capsule. 

Related Articles

Vascepa contains omega-3 acid known as eicosapentaenoic acid (EPA) in ethyl ester form. EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.

Vascepa is now available as 0.5g strength capsules in 240-count bottles and 1g strength capsules in 120-count bottles.

For more information call (855) 827-2372 or visit